Sernova Corp.  

(Public, CVE:SVA)   Watch this stock  
Find more results for SVA
-0.005 (-2.00%)
Feb 17 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.24 - 0.25
52 week 0.21 - 0.40
Open 0.25
Vol / Avg. 164,000.00/182,164.00
Mkt cap 38.39M
P/E     -
Div/yield     -
EPS -0.02
Shares 156.68M
Beta -0.13
Inst. own     -

Key stats and ratios

Q4 (Oct '16) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -10.51% -53.31%
Return on average equity -12.41% -60.00%
CDP Score - -


700 Collip Cir Suite 114
+1-519-8585184 (Phone)
+1-519-8585099 (Fax)

Website links


Sernova Corp. is a regenerative medicine company engaged in the research and development of its Cell Pouch and associated technologies, including therapeutic cells. The Company is focused on developing a treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted and prevascularized medical device (the Cell Pouch) and protected from immune system attack. The Cell Pouch is designed to create a microvessel rich, tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of serious, chronic diseases, such as diabetes, hemophilia and thyroid disease. Its lead program is the clinical development of the Cell Pouch for treatment of patients with insulin dependent diabetes. It is also evaluating Cell Pouch for the treatment of patients with hemophilia A. It uses Sertolin local immune protection technology.

Officers and directors

Frank A. Holler Chairman of the Board
Age: 57
Philip Toleikis President, Chief Executive Officer
Scott Langille Chief Financial Officer
Age: 59
James T. Parsons CPA Director
Bruce Weber Director
Jeffrey A. Bacha Independent Director
Age: 47